Barclays
SIOX

Barclays’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Barclays’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-144
Closed -$1K – 6595
2019
Q4 		$1K Sell
144
-9,856
-99% -$54.7K ﹤0.01% 6289
2019
Q3 		$65K Buy
+10,000
New +$69K ﹤0.01% 5770
2019
Q2 		– Sell
-238
Closed -$3K – 7411
2019
Q1 		$3K Buy
238
+188
+376% +$1.87K ﹤0.01% 6829
2018
Q4 		$0 Buy
50
+32
+178% +$461 ﹤0.01% 7491
2018
Q3 		$0 Sell
18
-18,327
-100% -$333K ﹤0.01% 7499
2018
Q2 		$332K Buy
18,345
+9,692
+112% +$143K ﹤0.01% 4303
2018
Q1 		$91K Sell
8,653
-10,464
-55% -$168K ﹤0.01% 5449
2017
Q4 		$806K Buy
19,117
+17,789
+1,340% +$798K ﹤0.01% 3331
2017
Q3 		$73K Sell
1,328
-9,131
-87% -$1.54M ﹤0.01% 5147
2017
Q2 		$1.94M Buy
10,459
+10,204
+4,002% +$1.79M ﹤0.01% 2266
2017
Q1 		$31K Sell
255
-437
-63% -$45.8K ﹤0.01% 5601
2016
Q4 		$68K Buy
692
+612
+765% +$64.4K ﹤0.01% 4978
2016
Q3 		$9K Buy
+80
New +$9.6K ﹤0.01% 5845

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays's SIOX Position: Q1 2020 in Review

Barclays sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2020, closing a stake of 144 shares — an estimated $1K sold.

Barclays first reported a position in SIOX in Q3 2016 and held it in 13 quarters. The position peaked at $1.94M in Q2 2017. 42 funds tracked by Wall St. Rank hold SIOX as of Q1 2020.

  • Barclays reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 144 Sio Gene Therapies Inc. Common Stock shares in Q1 2020, an estimated $1K.
  • Barclays first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2016 and held it in 13 quarters.
  • Barclays's Sio Gene Therapies Inc. Common Stock position peaked at $1.94M in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.